Navigation Links
NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
Date:9/21/2007

HIV virus, the immune system's fight against the infection, and the drugs administered to treat HIV. Painful HIV-DSP is characterized by significant pain in the feet and hands.

About NeurogesX, Inc.

NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including PHN, painful HIV-DSP and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX-4010 have been completed and have met their primary endpoints, two in PHN and one in HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, statements relating to the successful completion of the C119 clinical trial with respect to NeurogesX' lead product candidate, NGX-4010, including the timing of announcement of results from such trial; filing for regulatory approval and the timing of such filings; the ability to obtain approval for and commercialize NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not lim
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
2. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. LANI completes Phase I in Japan and to commence Phase I in UK
5. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
8. MediQuest Concludes Confirmatory Phase III Study of Raynaud’s Therapy
9. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/jq34zf/investigation ... Report on China,s Tobramycin Market, 2010-2019" report to ... whose eye drop and ointment are the most common ... inflammation caused by eye infection. Currently, dozens of enterprises ... produce tobramycin, among which the Top 5 are s.a. ...
(Date:8/28/2015)... , Aug. 28, 2015 ... announced the addition of the "Investigation Report ... their offering. Developed by AstraZeneca plc, ... an important drug for the treatment of schizophrenia. ... quetiapine was listed in the Catalogue of Drugs ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ) ... on China,s Ranibizumab Market, 2012-2019" report to their ... by CFDA to treat wet age- related macular degeneration ... Novartis, is available in the Chinese market. However, in ... the treatment of wet AMD in China ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
... IRIDEX Corporation (NASDAQ: IRIX ) today announced that it ... closes on Thursday, November 3, 2011.  In ... with the investment community at 5:00 p.m. Eastern Time ... to discuss the results of the quarter and other business developments. ...
... A potentially groundbreaking approach to predicting cancer patient ... electronic version of Science Magazine.  The paper describing the ... Letai and colleagues at Boston,s Dana Farber Cancer Institute. ... of the cancer cell to respond to chemotherapies. This ...
Cached Medicine Technology:Groundbreaking Approach to Predicting Cancer Patients' Response to Treatment Featured in Science Magazine 2
(Date:8/29/2015)... ... August 30, 2015 , ... Rio Salado College ... as the college’s Vice President of Strategic Initiatives and Information Services. O’Shea, who has ... the college expand its reach and impact through innovative technologies and strategies. , “I ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... two inventors from Miller Place, N.Y. "I specialize in manual therapy, and my ... addition, it can be used for additional muscle dysfunction throughout the body." , ...
(Date:8/29/2015)... ... August 29, 2015 , ... Brands like Toppik , Eau Thermale ... costs. , “Before, a threshold of $49.00 was required to qualify for free standard ... for free standard shipping for customers regardless of the item’s selling price.” , With ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... localized area with stretching, soft tissue manipulation. Platelet rich plasma injections also have ... through research to improve treatment outcomes. This localized treatment seems to address ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Decatur County Memorial Hospital recently transitioned management companies to partner with Wound Care ... for their outpatient wound center. , Transitioning wound care management providers can ...
Breaking Medicine News(10 mins):Health News:Rio Salado College Appoints New Vice President of Strategic Initiatives and Information Services 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... Royal Brisbane and Women's Hospital (RBWH), Sydney struggles with ... in three wards were found with a bacterium ... skin. ,To prevent the spread, 12 patients ... cent burns) were shifted to Sydney hospital and some ...
... medical colleges in West Bengal continued to be paralysed ... stir against the Centre's decision to introduce OBC quota ... interns, housestaff and post graduate trainees in nine medical ... dental colleges boycotted classes as well as out patient ...
... drugs, used by patients with enlarged hearts// (dilated ... Scientists with the Multicenter defibrillators in Nonischemic ... sudden cardiac deaths with cardiomyopathy due to a ... these about, 229 patients were randomly selected to ...
... A study conducted by Cancer Research UK says 'Teens who tried ... never tried it to take up smoking' //.Again after 3 years ... Research UK said anti-smoking campaigns should focus on preventing children trying ... found around 14% of 11-year olds and 62% of 15-year olds ...
... Ahmedabad-based Dishman Pharmaceuticals and Chemicals Ltd today said ... US-based Solutia Inc for 74.5 million dollars. // ... for purchasing 100 per cent stake in CarboGen ... in a statement., ,The acquisition includes other ...
... Ranbaxy Laboratories Limited today said the World Health Organistion ... (ARV) products in its pre-qualification list. // ... Efavirenz 200mg capsules, Stavudine 30mg capsules, Stavudine 40mg capsules, ... a significant development. We strongly feel that Generic ARVs ...
Cached Medicine News:
Super High Density, multi-frequency, convex array, small footprint transducer for scanning during craniotomies....
... is our High Penetration Steered Linear Peripheral ... 3 to 8 MHz. It is ... Harmonic Detection with 4 different settings to ... vessels. The high color and Doppler sensitivity ...
Super High Density, multi-frequency, end-fire phased array transducer. Point-and-shoot scanning is the benefit of this transducer....
HST, multi frequency Side Fire "T intraoperative transducer. A wide field of view is this transducers benefit....
Medicine Products: